


"Redacted Copy"

Section 4.1 – Applicant Information (requested form only)



FORM 1: APPLICANT GENERAL INFORMATION

Applicant Information				
Applicant Name				
Bedner Growers, Inc.				
Mailing Address				
10066 Lee Road				
City	Apt/Ste #	State	ZIP Code	Country
Boynton Beach		FL	33473	USA

Contact Information		
First Name	Last Name	Middle Initial
I. Jeffrey	Pheterson	
Telephone Number	Designated Email (for Department/Applicant Communications)	
561-239-0025	jpheterson@warddamon.com	

Medical Director Information		
First Name	Last Name	Middle Initial
Darryl	Appleton	E.
Florida Physician (MD or DO) License Number	Telephone Number	Email
ME87656	561-450-8328	info@sleepandfatigue.com

Section 4.2 – Declaration of Exempt Information (no page limit)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.3 – Certificate of Registration, DACS Documentation, and Background

Screening (no page limit)

"Redacted Copy"

Subsection 4.3.1 – Florida Business Registration (no page limit)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.3.2 – DACS Documentation(no page limit)

"Redacted Copy"

"Redacted Copy"

Subsection 4.3.3 – Level 2 Background Screening(no page limit)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.4 – Plan for Cultivating Marijuana and Supporting Infrastructure

"Redacted Copy"

Subsection 4.4.1 – Cultivation Plan (10 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.4.2 – Cultivation Infrastructure (7 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.4.3 – Ability to Secure Cultivation Infrastructure (7 page max)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.5 – Plan for Processing Marijuana and Supporting Infrastructure

"Redacted Copy"

Subsection 4.5.1 – Processing Plan (10 pages maximum)]

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.5.2 – Processing Infrastructure (7 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.5.3 – Ability to Secure Processing Infrastructure (7 pages maximum)]

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.6 – Plan for Dispensing Marijuana and Supporting Infrastructure

"Redacted Copy"

Subsection 4.6.1 – Dispensing Plan (10 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.6.2 – Dispensing Infrastructure (7 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.6.2 – Addendum

"Redacted Copy"

"Redacted Copy"

Subsection 4.6.3 – Ability to Secure Dispensing Infrastructure (7 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.7 Plan for Security and Accountability

"Redacted Copy"

Subsection 4.7.1 – Premises Security (6 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.7.1 – Addendum

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.7.2 – IT Security (6 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.7.3 – Diversion, Unlawful Access, and Transportation (6 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.7.4 – Personnel Screening and Training (4 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.7.5 – Recalls (3 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.8 – Ability to Execute Proposed Plans

"Redacted Copy"

Subsection 4.8.1 – Experience in the Marijuana Industry (5-pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.8.2 – Other Relevant Experience (5 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.8.3 – Business Plan (5 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.8.4 – Prior Enforcement Action (no page limit)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.9 – Medical Director

"Redacted Copy"

Subsection 4.9.1 – Experience in the Marijuana Industry (4 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.9.2 – Other Relevant Experience (2 pages maximum)

"Redacted Copy"

"Redacted Copy"

4.9.2 – Addendum

"Redacted Copy"



DARRYL APPLETON, M.D., D, ABPN, D, ABSM, FAASM, CIME

AREAS OF PRACTICE

- Cannabis Medicine (Canada), Neuropsychiatry, Sleep Medicine, Psychopharmacology, Substance Dependence
- Board Certified by American Board of Psychiatry & Neurology
- Board Certified by the American Board of Sleep Medicine
- Board Certified by the American Board of Independent Medical Examiners
- Board Certified by American Board of Preventative Medicine – Addiction Medicine

EDUCATION

2003 – 2004	Fellowship - University Network Hospital, Toronto Western Hospital, University of Toronto, Toronto, Canada (Largest psychiatry residency in North America)
1999 – 2003	Residency – Adult Psychiatry – University of Miami, Jackson Memorial Hospital, Miami, FL (2 nd largest hospital in USA)
1995 – 1999	M.D., Ross University School of Medicine, Dominica, West Indies.
1991 – 1994	Bachelor of Science in Psychology, University of Toronto, Toronto, Canada

PROFESSIONAL EXPERIENCE

2003 – present	Medical Director, Appleton Clinic, North York, ON, Canada (Cannabis Medicine, Sleep Medicine, Neurology, Psychiatry)
2006 – present	Medical Director, Sleep & Fatigue Treatment Center / Appleton Clinic Boca Raton, FL (Sleep Medicine/Addiction/Neuropsychiatry)
2017 - 2017	Medical Director – Boca Detox / Immersion Recovery Center (Drug and Alcohol Rehabilitation)
2009 – 2012	Medical Director – SDR Sleep Diagnostics – Miami, FL (Sleep Medicine, Research)
2010 – 2015	Co-Medical Director, BrainStim, LLC, Delray Beach, FL (Transcranial Magnetic Stimulation, Neurological Psychiatric Practice)



A SLEEP CLINIC WITH A DIFFERENCE

- 2009 – 2015 Medical Director, Mandala Healing Center, West Palm Beach, FL
(Substance Dependence)
- 2003 – 2007 Associate, Sleep & Alertness Clinic, University of Toronto, Division of
Neuropsychiatry, Toronto Western Hospital, Toronto, Canada
(Neuropsychiatry and Sleep Medicine)
- 2003 - 2014 Reviewer, Psychosomatic Medicine (Journal)

CERTIFICATIONS

- FRCPS(C) Fellow, Royal College of Physicians & Surgeons, Canada
CPSO College of Physicians and Surgeons, Ontario
MCC Medical College of Canada
ABSM Diplomate, American Board of Sleep Medicine
ABPN Diplomate, American Board of Psychiatry and Neurology
ABPM Certification in Addiction Medicine American Board of Preventative
Medicine
ACLS Advanced Cardiac Life Support
CIME Certified, American Board of Medical Examiners
ABPM Diplomate, American Board of Preventative Medicine, Addiction
Medicine

RESEARCH EXPERIENCE

- Sub Investigator, EQUAL Clinical Research Initiative, Medical Cannabis, 2016
Sub Investigator, Tilray Observational Patient Study (TOPS), Medical Cannabis, 2015
Sub Investigator, Novo Nordisk, Type II Diabetes, 2011
Sub Investigator, Novo Nordisk, Type II Diabetes, 2011
Sub Investigator, Novo Nordisk, Type II Diabetes, 2011
Sub Investigator, Merck, Type II Diabetes, 2011
Sub Investigator, Merck, Overactive Bladder, 2011
Sub Investigator, GSK, Type II Diabetes, 2011
Sub Investigator, Furiex, IBS with Diarrhea, 2010
Sub Investigator, Salix, Ulcerative Colitis, 2010
Sub Investigator, Johnson & Johnson, Low Back Pain, 2010
Sub Investigator, Merck, Migraine, 2010
Sub Investigator, Novo Nordisk, Type II Diabetes, 2010
Sub Investigator, Merck, Osteoporosis for women, 2010
Sub Investigator, Merck, Diabetes Mellitus for elderly Patients, 2010
Sub Investigator, Merck, Type 2 DM and Inadequate Glycemic Control, 2010
Sub Investigator, Merck, Osteoporosis for men, 2010
Sub Investigator, Novo Nordisk, Type II Diabetes, 2010
Sub Investigator, Takeda, Major Depressive Disorder, 2009



A SLEEP CLINIC WITH A DIFFERENCE

Sub Investigator, Pfizer, Refinement of Patient Reported Outcomes Instruments in Subjects with Insomnia Characterized by Nonrestorative Sleep, 2009
Sub Investigator, Pfizer, Primary Insomnia in Adults, 2009
Sub Investigator, Sanofi-Aventis Pharmaceuticals, Primary Insomnia Characterized by Sleep Maintenance Difficulty, 2009
Sub Investigator, Merck, Migraine Prophylaxis in Patients with Episodic Migraine, 2009.
Sub Investigator, Arena, Primary Insomnia Characterized by Difficulty Maintaining Sleep, 2009.
Sub Investigator, Takeda, Generalized Anxiety Disorder, 2008.
Sub Investigator, Pfizer, Adults with Nonrestorative Sleep, 2008.
Sub Investigator, Merck, Excessive Daytime Sleepiness in Obstructive Sleep Apnea/Hypopnea Syndrome, 2008.
Sub Investigator, Organon, Elderly Insomnia, 2008.
Sub Investigator, Takeda Pharmaceuticals, Chronic Insomnia, 2008
Sub Investigator, Actelion Pharmaceuticals, Elderly Insomnia, 2008
Sub Investigator, Vanda Pharmaceuticals, Primary Insomnia, 2008
Sub Investigator, Arena Pharmaceuticals, Obesity, 2008
Sub Investigator, Sanofi-Aventis Pharmaceuticals, Overactive Bladder, 2008
Sub-Investigator, Broward Research Group, Inc. / Miami Research Associates (Clinical Research Studies: Phase II to Phase IV – Psychiatry / Sleep Medicine) 2008
Principal Investigator: SDR Clinical Research, LLC. Hollywood, FL. (Clinical Research Studies: Phase II to Phase IV) 2010-2012
Sub-Investigator/ Principal Investigator: Suncoast Research Group, LLC. Miami, FL (Clinical Research Studies: Phase II to Phase IV) 2010-2012
Sub-Investigator/ Principal Investigator: Suncoast Research Group, LLC. Hialeah, FL (Clinical Research Studies: Phase II to Phase IV) 2010-2012
Sub-Investigator: Miami Research Associates (Clinical Research Studies: Phase II to Phase IV – Psychiatry / Sleep Medicine) 2008-2009

PUBLICATIONS

Appleton D, Mental Notes Magazine, *Sleep and Circadian Rhythms through the Life Span*, Winter 2008:7-9.

Shen J, Chung SA, Kayumov L, Moller H, Hossain N, Wang X, Deb P, Sun F, Huang X, Novak M, Appleton D, Shapiro CM. *Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine*. Canadian Journal of Psychiatry 2006; 51(1):27-33.

Quality Assessment study of the Pediatric Endocrinology Department at Brookdale University Hospital and Medical Center (DCCT Trial Analog), Bazan, J; Appleton, D; Tam-



Talamayan, C. Advisor: AvRuskin, T. M.D., Director of Pediatrics, Pediatric Endocrinology Research Lab, Brookdale University Hospital and Medical Center. 2003

Stress and Anxiety Clinical Research Unit, Institute of Mental Health Research, Royal Ottawa Hospital: Advisor: Bradwejn, J. M.D. FRCP(C), Director of Psychiatry, “*Predictors of Illness Intrusiveness in Patients with Anxiety Disorders*”, Koszycki, D; Appleton, D; Katzman, M; Bradwejn, J. 2002

PROFESSIONAL ASSOCIATIONS

AASM (American Academy of Sleep Medicine)
AMA (American Medical Association)
CMA (Canadian Medical Association)
OMA (Ontario Medical Association)

APA (American Psychiatric Association)
SFPS (South Florida Psychiatric Society)
CPA (Canadian Psychiatric Association)

MEDICAL LICENSES

Florida Board of Medicine
Ontario Medical License

AWARDS

Patients' Choice 5th Anniversary Award (2008-2017)
Patients' Choice Award (2008-2017)
Compassionate Doctor Recognition (2010-16)
Compassionate Doctor Award – 5 Year Honoree (2014, 2016)
Top 10 Doctor - Metro Area (2014/2015)
Top 10 Doctor - State (2014-2017)
On-Time Doctor Award (2014-17)

EXPERT TESTIMONY

In 2015, Dr. Appleton testified as an expert witness on medical marijuana before a Senate Committee in the Florida Legislature. As a Board Certified Independent Medical Examiner, Dr. Appleton testified as an Expert Witness in both Canada and in the US in court cases involving cannabis medicine.

Subsection 4.9.3 – Oversight (4 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.9.4 – Managing Conflicts of Interest (1 page maximum)

"Redacted Copy"

Subsection 4.9.5 – Medical Director Acknowledgment and Certificate of Course

Completion (requested documentation only)

"Redacted Copy"

Section 4.10 – Personnel

"Redacted Copy"

Subsection 4.10.1 – Personnel Qualifications (10 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.10.1 – Addendum

"Redacted Copy"

Subsection 4.10.2 – Drug-Free Workplace (2 pages maximum)

"Redacted Copy"

"Redacted Copy"

Subsection 4.10.3 – Personnel Training (6 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.11 – Diversity Plan

"Redacted Copy"

Subsection 4.11.1 - Diversity Plan (4 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.11.2 - Implementation of Diversity Plan (4 pages)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.12 – Certified Financial Statements and Available Funding

"Redacted Copy"

Subsection 4.12.1 – Certified Financial Statements (requested documents only)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.12.2 – Available Funding (6 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.12.2 – Available Funding Addendum

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.12.3 – Projected Budget (4 pages maximum)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.12.3 – Addendum

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.13 – Business Ownership and Structure

"Redacted Copy"

Subsection 4.13.1 – Ownership Information for Individual (Natural Person) Applicants

Not applicable

Subsection 4.13.2 – Ownership Information for Entity Applicants (requested documents and information only)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Subsection 4.13.3 – Capitalization Tables, Change of Control, and Related Entities

(requested documents and information only)

"Redacted Copy"

"Redacted Copy"

Section 4.14 – Applicant Acknowledgment (requested form only)

"Redacted Copy"

"Redacted Copy"

"Redacted Copy"

Section 4.15 – Citrus Preference Documentation

"Redacted Copy"

Section 4.16 - *Pigford/BFL* Application Fee Transfer Request

"Redacted Copy"